AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AFT PHARMACEUTICALS LTD

3.560

0.000

Volume:- -

Turnover:- -

Market Cap:373.32M

PE:30.54

High:3.560

Open:3.560

Low:3.560

Close:3.560

52wk High:4.130

52wk Low:2.431

Shares:104.87M

Float Shares:30.50M

Volume Ratio:- -

T/O Rate:- -

Dividend:0.02

Dividend Rate:0.57%

EPS(TTM):0.117

EPS(LYR):0.140

ROE:13.66%

ROA:7.90%

PB:4.21

PE(LYR):25.43

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

AFT Pharmaceuticals on Track for Fiscal 2027 Revenue, Profit Targets

MT Newswires Live

AFT Pharmaceuticals Signs Exclusive Japan Deal for Non-Opioid Painkiller

MT Newswires Live

Indonesia, Australia Renew Anti-Drug Cooperation Through 2031

AFT Pharmaceuticals Offers an Attractive Risk-Reward Profile With an Expanding Clinical Pipeline, Pitt Street Research Says

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/AFP.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"AFP.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"AFP.AU\",,,,,undefined,":{"symbol":"AFP.AU","market":"AU","secType":"STK","nameCN":"AFT PHARMACEUTICALS LTD","latestPrice":3.56,"timestamp":1791417736419,"preClose":3.56,"halted":0,"volume":0,"delay":0,"changeRate":0,"nameEN":"AFT PHARMACEUTICALS LTD","floatShares":30495171,"shares":104866260,"eps":0.116558,"marketStatus":"Trading","change":0,"latestTime":"10-08 12:28:45 AEDT","open":3.56,"high":3.56,"low":3.56,"amount":0,"amplitude":0,"askPrice":3.99,"askSize":1090,"bidPrice":3.61,"bidSize":78,"shortable":3,"etf":0,"ttmEps":0.116558,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791435600000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":3.56,"dividendRate":0.005818,"openAndCloseTimeList":[[1791414000000,1791435600000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"AFP.AU","preClose":3.54,"auctionPrice":3.56,"auctionVolume":2333,"auction":3,"marketStatus":"盘后竞价","timestamp":1791349208631}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"AFP.AU\",,,,,undefined,":{"symbol":"AFP.AU","floatShares":30495171,"roa":"7.90%","roe":"13.66%","lyrEps":0.14,"shares":104866260,"dividePrice":0.020115,"high":3.56,"amplitude":0,"preClose":3.56,"low":3.56,"week52Low":2.431,"pbRate":"4.21","psRate":"1.82","week52High":4.13,"institutionHeld":0,"latestPrice":3.56,"committee":-0.866438,"eps":0.116558,"divideRate":0.00565,"volume":0,"delay":0,"ttmEps":0.116558,"open":3.56,"prevYearClose":2.977,"prevWeekClose":3.45,"prevMonthClose":3.45,"prevQuarterClose":3.45,"fiveDayClose":3.45,"twentyDayClose":3.49,"sixtyDayClose":3.19,"dividendPayoutRate":0.14266949070534046,"dividendFrequency":"A","dividendGrowthYears":2,"dividendGrowthRate":0.13433952002175528,"fiveYearAvgDividendRate":0.005418883467340146},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AFP.AU\",params:#limit:5,,,undefined,":[{"date":"2026-06-18","symbol":"AFP.AU","amount":0.029411700000000002,"announcedDate":"2026-05-21","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-06-19","defaultRemindTime":1781740800000,"name":"AFT PHARMACEUTICALS LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-07-03","payableDate":"2026-06-19","currency":"NZD","dateTimestamp":1781704800000,"payDate":"2026-07-03"},{"market":"AU","date":"2026-05-21","symbol":"AFP.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1779285600000,"reportTimeType":"","actualEps":null},{"date":"2025-06-18","symbol":"AFP.AU","amount":0.018,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-06-19","defaultRemindTime":1750204800000,"name":"AFT PHARMACEUTICALS LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-04","payableDate":"2025-06-19","currency":"NZD","dateTimestamp":1750168800000,"payDate":"2025-07-04"},{"date":"2024-06-19","symbol":"AFP.AU","amount":0.016,"announcedDate":"2024-05-23","type":"dividend","market":"AU","newRecordDate":"2024-06-20","defaultRemindTime":1718755200000,"name":"AFT PHARMACEUTICALS LTD","recordDate":"2024-07-04","payableDate":"2024-06-20","currency":"NZD","dateTimestamp":1718719200000,"payDate":"2024-07-04"},{"date":"2023-06-16","symbol":"AFP.AU","amount":0.011,"announcedDate":"2023-05-22","type":"dividend","market":"AU","newRecordDate":"2023-06-19","defaultRemindTime":1686873600000,"name":"AFT Pharmaceuticals","recordDate":"2023-07-04","payableDate":"2023-06-19","currency":"NZD","dateTimestamp":1686837600000,"payDate":"2023-07-04"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AFP.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2023-06-16","recordDate":"2023-06-19","paymentDate":"2023-07-04","value":0.011,"currency":"NZD"},{"executeDate":"2024-06-19","recordDate":"2024-06-20","paymentDate":"2024-07-04","value":0.016,"currency":"NZD"},{"executeDate":"2025-06-18","recordDate":"2025-06-19","paymentDate":"2025-07-04","value":0.018,"currency":"NZD"},{"executeDate":"2026-06-18","recordDate":"2026-06-19","paymentDate":"2026-07-03","value":0.029411700000000002,"currency":"NZD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AFP.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673082466","title":"AFT Pharmaceuticals on Track for Fiscal 2027 Revenue, Profit Targets","url":"https://stock-news.laohu8.com/highlight/detail?id=2673082466","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673082466?lang=en_us&edition=fundamental","pubTime":"2026-10-06 05:57","pubTimestamp":1791237424,"startTime":"0","endTime":"0","summary":"AFT Pharmaceuticals  remains on course to deliver its fiscal 2027 revenue target of NZ$300 million and operating profit guidance of NZ$28 million to NZ$32 million, supported by double-digit first-half revenue growth across all divisions, according to a Tuesday filing with the Australian and New Zealand bourses.Key developments include the out-licensing of Maxigesic IV in Japan and the Philippines; positive phase one vaccine results published in The Lancet, further validating StablePharma's fridge-free medicine technology; and tentative US Food and Drug Administration approval for Scomara, marking the company's third patented product approval in the US, per the filing.The company has also launched Maxigesic Rapid in the US through Mark Cuban's Cost Plus Drugs, while its Feramyl IV injectable iron product has entered a large-scale clinical study involving 1,366 patients, the filing said.The fiscal 2027 research and development spending is expected to reach NZ$23 million to NZ$25 million,","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AFP.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670043244","title":"AFT Pharmaceuticals Signs Exclusive Japan Deal for Non-Opioid Painkiller","url":"https://stock-news.laohu8.com/highlight/detail?id=2670043244","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670043244?lang=en_us&edition=fundamental","pubTime":"2026-09-28 06:22","pubTimestamp":1790547746,"startTime":"0","endTime":"0","summary":"AFT Pharmaceuticals  entered an exclusive development, licensing, and supply agreement with Japan's Mikasa Seiyaku to develop and commercialize its non-opioid intravenous painkiller Maxigesic IV in Japan, according to a Monday filing with the Australian and New Zealand bourses.The company will develop and supply the product, while Mikasa will oversee regulatory submissions to Japan's Pharmaceuticals and Medical Devices Agency, obtain marketing authorization and commercialize the treatment, per the filing.The company will receive an upfront licensing fee, development milestone payments, and royalties on post-launch sales under the agreement, the filing added.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","AFP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669512044","title":"Indonesia, Australia Renew Anti-Drug Cooperation Through 2031","url":"https://stock-news.laohu8.com/highlight/detail?id=2669512044","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669512044?lang=en_us&edition=fundamental","pubTime":"2026-09-24 11:38","pubTimestamp":1790221081,"startTime":"0","endTime":"0","summary":"TEMPO.CO, Jakarta-The Indonesian National Narcotics Agency  and the Australian Federal Police  have extended their law enforcement partnership through 2031 to combat transnational drug trafficking, including emerging threats such as drug-infused liquid vapes.The five-year extension of a memorandum of understanding  on combating illicit narcotics, psychotropic substances and precursor trafficking was signed in Bali on Tuesday, Sept. 22, 2026, by BNN Chief Commissioner General Suyudi Ario Seto and AFP Commissioner Krissy Barrett.In a statement confirmed onWednesday, Sept. 23, 2026, Suyudi said the borderless nature and technological sophistication of modern drug networks require an adaptive and coordinated international response.","market":"nz","thumbnail":"https://statik.tempo.co/data/2026/01/06/id_1451778/1451778_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2026/01/06/id_1451778/1451778_720.jpg"],"rights":{"source":"tempo_highlight","url":"https://en.tempo.co/read/2120221/indonesia-australia-renew-anti-drug-cooperation-through-2031","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/2120221/indonesia-australia-renew-anti-drug-cooperation-through-2031","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["QRE.AU","AFP.AU","BBOZ.AU","EIGA.AU","BK4185","THC.AU","LU0130103400.USD","IIGF.AU","IOZ.AU","BEAR.AU","LU1201861165.SGD","ZYAU.AU","LU2324357040.USD","IMLC.AU","BK7096","LU0963586101.USD","OZR.AU","SLF.AU","XJO.AU","XKO.AU","DACE.AU","IISV.AU","GEAR.AU","E200.AU","OZF.AU","XAO.AU","GIVE.AU","LU0648000940.SGD","QFN.AU","VAS.AU","VAP.AU","THC","STW.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653770203","title":"AFT Pharmaceuticals Offers an Attractive Risk-Reward Profile With an Expanding Clinical Pipeline, Pitt Street Research Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2653770203","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653770203?lang=en_us&edition=fundamental","pubTime":"2026-07-24 10:09","pubTimestamp":1784858980,"startTime":"0","endTime":"0","summary":"AFT Pharmaceuticals (ASX:AFP, NZE:AFT) represented an attractive risk-reward profile for equity investors given the company's two-decade growth record, active US commercialization, and expanding inter","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","AFP.AU","AFT"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/AFP.AU\",params:#limit:6,delay:true,,,undefined,":[]}}